Presentation Abstract

Abstract Number: 682
Presentation Title: Dual inhibition of BER by TRC102 and PARP inhibitor (ABT 888) synergistically enhances cytotoxicity of TMZ in human melanoma
Presentation Time: Sunday, Apr 18, 2010, 2:00 PM - 5:00 PM
Location: Exhibit Hall A-C, Poster Section 25
Poster Section: 25
Poster Board Number: 19
Author Block: Alina D. Bulgar1, Yanling Miao1, Stanton L. Gerson2, Lili Liu2. 1Case Western Reserve University, Cleveland, OH; 2Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH
Abstract Body: Melanoma, the most fatal skin cancer, has increased in incidence by 15-fold in the past 40 years, the fastest rate increase of any human malignancy. This disease metastasizes rapidly and is highly resistant to chemotherapy. Currently, temozolomide (TMZ) is an important part of treatment regimens for advanced metastatic melanoma. However, drug resistance often results in treatment failure. A major resistance factor is the presence of elaborate mechanisms of DNA repair. We have previously studied the role of base excision repair (BER) in conferring TMZ resistance and explored a combined therapy by targeting BER with methoxyamine (TRC102), an inhibitor of BER, which binds to abasic sites and disrupts the BER pathway. The potentiation of TMZ by TRC102 has been validated in different tumor types in vitro and in xenograft models. Results showed TRC102 potentiation of TMZ was accompanied by a remarkable induction of DNA strand breaks. In this study, we examined the therapeutic efficacy of the combination of TMZ with TRC102 and a PARP inhibitor (ABT888) in three melanoma cell lines (A375, WM9, and WM164) and in melanoma xenografts. PARP, an enzyme critical in BER pathway, is actively involved in the repair of DNA strand breaks. We hypothesized the inhibition of PARP would inhibit BER with the accumulation of large numbers of unrepaired DNA strand breaks and the combination of TRC102 and ABT888 would synergistically enhance the anti-tumor effect of TMZ through dual inhibition of BER. Results showed that compared to TMZ alone, the combination with either ABT888 or TRC102 more effectively inhibited cell viability and induced apoptosis in A375 and WM9, but not in WM164 melanoma cell lines. The resistance in WM164 cells is probably related to a deficiency in methylpurine-DNA glycosylase, which is responsible for removing TMZ-induced methylated DNA adducts (N7mG and N3mA) and producing toxic AP sites. When combined with TMZ and TRC102, ABT888 at a concentration of 5 µM efficiently potentiated cytotoxicity by 8-10 fold in A375 and WM9 melanoma cell lines, respectively, and 4 fold in WM164 cells. Cytotoxicity was correlated with the induction of DNA single and double stranded breaks as assayed by comet assay and induction of γ-H2AX. For in vivo studies, the therapeutic regimen was initiated when tumor xenografts (WM9) in nude mice reached ~100 mm3 in volume and treatment was continued for 5 days. Tumor volume was measured for assessment of therapeutic effect. At termination, we found 30-40% reduction in tumor volume following treatment with the combination of TMZ with ABT888 or with TRC2, and 80% reduction in tumor volume by combining the three drugs relative to the TMZ alone group, which had no significant differences in tumor growth in comparison to untreated group. Data indicate that combining a PARP inhibitor with TMZ and TRC102 results in greater inhibition of BER and induces a synergistic cytotoxic effect.